Likewise, FTO undertakes oncogenic functions in GBM program (Cui et al. 2017; Su et al. 2018), and MA2, the FTO chemical inhibitor, can coordinately prolong the life span in GSC-transplanted mice (Cui et al. 2017), suggesting that FTO-regulated m6A awaits to be a promising therapeutic target for GBM treatment. The gene discussed is FTO; the disease is glioblastoma.